Responses
Clinical/translational cancer immunotherapy
Original research
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
